Galmed Pharmaceuticals Ltd. (GLMD) News

Galmed Pharmaceuticals Ltd. (GLMD): $0.58

-0.03 (-5.28%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add GLMD to Watchlist
Sign Up

Industry: Biotech


Ranked

of 503

in industry

Filter GLMD News Items

GLMD News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest GLMD News From Around the Web

Below are the latest news stories about Galmed Pharmaceuticals Ltd that investors may wish to consider to help them evaluate GLMD as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Good morning, trader!

William White on InvestorPlace | March 18, 2022

Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt

Galmed Pharmaceuticals Ltd. (NASDAQ-CM: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today that the United States Patent and Trademark Office (USPTO) granted Galmed new patents related to the use of Aramchol for the treatment of fibrosis and for the treatment for modulating gut microbiota. An additional patent grant protects the low dose composition of Aramchol salt until June 8, 2036. With these latest pat

Yahoo | January 11, 2022

Galmed announces positive results of Phase 1 study of Amilo-5MER

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today results of a Phase 1 clinical trial of Amilo-5MER in healthy volunteers that demonstrated an excellent safety profile and tolerability.

Yahoo | January 10, 2022

Analysts Are Bullish on Top Healthcare Stocks: ImmunoGen (IMGN), TG Therapeutics (TGTX)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ImmunoGen (IMGN – Research Report), TG Therapeutics (TGTX – Research Report) and Galmed Pharmaceuticals (GLMD – Research Report) with bullish sentiments. ImmunoGen (IMGN) In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on ImmunoGen, with a price target of $12.00. The company's shares closed last Tuesday at $6.17. According to TipRanks.

Catie Powers on TipRanks | December 1, 2021

Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial Results

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and fibrosis, provides today updated information on the Company's scientific and clinical development programs and reports financial results for the three and nine months ended September 30, 2021.

Yahoo | November 8, 2021

Galmed Announces New Positive Data from Ongoing ARMOR Study Open Label Part Showing Clinically Significant Effect on Fibrosis Improvement

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today results from histology and biomarkers analyses in the ongoing Open-Label Part of the ARMOR Phase 3 study.

Yahoo | November 8, 2021

Galmed Reveals Early Aramchol Data From Late-Stage NASH Trial

Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) announced results from the first 16 patients in the Open-Label Part of the ARMOR Phase 3 study who underwent a scheduled post-baseline biopsy. ARMOR is assessing the evaluate the safety and efficacy of Aramchol for the treatment of NASH and fibrosis. Treatment with Aramchol reduced fibrosis progression in 15 out of the 16 patients. 8 out of the 16 patients (50%) showed fibrosis improvement by more than 1 point. In 3 patients (19%), fibrosis was reduced b

Yahoo | November 1, 2021

Galmed Announces Positive Results from First 16 Patients in Open-Label Part of ARMOR Study

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today results from the first 16 patients in the Open-Label Part of the ARMOR Phase 3 study who underwent a scheduled post-baseline biopsy.

Yahoo | November 1, 2021

Results of Galmed's Phase 2b ARREST Trial of Aramchol Published in Nature Medicine

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today that the one-year results of the global Phase 2b randomized placebo-controlled ARREST Trial of Aramchol in patients with NASH have been published in Nature Medicine (https://www.nature.com/articles/s41591-021-01495-3).

Yahoo | October 11, 2021

Trillium (TRIL) to be Acquired by Pfizer for $2.3 Billion

Trillium (TRIL) is set to be acquired by Pfizer for $2.3 billion or $18.50 per share. Stock shoots up.

Yahoo | August 24, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5028 seconds.